How Recordati is accelerating medical insight with AI

Medical Information (MI) teams are under pressure. As the volume of scientific literature grows and healthcare professionals (HCPs) face increasing time constraints.

Delivering timely, accurate, and evidence-based responses is more challenging than ever. For global pharmaceutical company Recordati, the challenge was clear: empower MI teams to respond faster and more comprehensively — while staying fully compliant and evidence‑based.

The solution: A collaboration with Elsevier and technology partner AVAYL that’s reshaping how trusted scientific content is accessed, analyzed and delivered.

The result: Faster responses grounded in high‑quality evidence.

As an R&D-intensive company, Recordati invests heavily in innovation — in 2024 alone it invested €286 million in research and development. Rapid evidence analysis across the product lifecycle — from R&D to Medical Affairs — is mission-critical.

The MI mandate: precision under pressure

MI teams are the first line of response for unsolicited medical queries from HCPs, patients and caregivers. Their remit is strictly non-promotional — and deeply specialised.

From drug efficacy and safety to off-label use, their responses must be fast, accurate and grounded in the latest evidence.

"Our work directly impacts patient care,” says Michelle Bridenbaker, Vice President and Head of Global Medical Information at Recordati. “Every inquiry from a healthcare professional or patient represents a real-world clinical scenario. The speed and quality of our response can impact patient treatments and outcomes.”

To meet this demand, MI teams rely on trusted biomedical databases like Elsevier’s Embase — a comprehensive biomedical database recognized by regulators as a premier biomedical literature resource. But even with robust resources, the sheer volume of literature can be overwhelming.

The AI opportunity — and the governance imperative

AI offers a compelling solution: the ability to screen vast numbers of publications quickly, surface relevant evidence and accelerate response times. But there’s a catch. To be valuable in MI, AI must operate with clear guardrails: use trusted, licensed content, preserve transparency for audit, and align with regulatory expectations for evidence handling.

“We saw the immense potential of AI to enhance our capabilities. The question was how could we confidently use our advanced tools on comprehensive biomedical literature datasets while remaining fully compliant?” says Bridenbaker.

A tailored framework for responsible innovation

Recognizing Elsevier’s mix of trusted content and technical expertise Recordati and AVAYL approached Elsevier as a strategic innovation partner.

Together, the three organisations co-developed a tailored framework that integrates Embase and ScienceDirect full-text article datasets into Recordati’s AI-powered workflow, securely and compliantly. At the heart of this collaboration is MedPro, AVAYL’s purpose-built AI platform for Medical Affairs.

The solution combines technical architecture, licensing models and legal safeguards to ensure that scientific content is used responsibly and effectively, with experts firmly in the driver’s seat.

“Our goal is to partner with our customers so that they can innovate with confidence. Pairing MedPro’s workflow with Elsevier’s trusted content means MI teams spend less time searching and more time creating comprehensive, evidence-based responses,” says Mirit Eldor, Managing Director, Elsevier, Life Science Solutions

Dr Miena Amiri, CEO of AVAYL agrees:

“By aligning technical safeguards, licensing models and legal frameworks from the start, we’re proving that AI can be implemented in a way that meets the needs of users while protecting the rights of content owners. It’s not about compromise — it’s about designing AI systems that create lasting value for all stakeholders.”

What has changed for Recordati’s MI team

• Faster triage and review: searches across the Embase dataset can be screened with AI to surface the most relevant evidence quickly, reducing manual effort.

• Higher-quality, consistent responses: MI specialists build responses from a single, trusted evidence base with clear version control.

• Experts focus where it matters: automation handles routine, repeatable tasks; clinicians and scientists focus on complex analysis and clinical context.

• Audit-ready by default: transparent source trails and role-based approvals support internal and external audit needs.

For Recordati’s MI team, the impact was immediate. They can now move from search to evidence-backed response more quickly, freeing their experts to focus on complex analysis and strategic tasks — ultimately improving the quality of support they provide to HCPs and patients.

Real impact, real outcomes

As AI continues to reshape research and clinical workflows, partnerships like this offer a blueprint for sustainable, scalable and legally sound progress, and show that AI innovation doesn’t have to come at the expense of compliance.